Breaking News Instant updates and real-time market news.

ACAD

Acadia

$20.58

0.86 (4.36%)

14:08
01/10/19
01/10
14:08
01/10/19
14:08

Acadia jumps after higlighting Nuplazid opportunity in PDP treatment

Shares of Acadia (ACAD), a biopharmaceutical company focused on central nervous system disorders, are rising after its presentation at the JP Morgan Healthcare Conference Wednesday night. SIGNIFICANT COMMERCIAL OPPORTUNITY FOR NUPLAZID: Nuplazid is a selective serotonin inverse agonist/antagonist, or SSIA, used to treat Parkinson's disease psychosis. During the JP Morgan conference, Acadia said it anticipated 2018 Nuplazid revenue of $220M-$225M, with Q3 Nuplazid revenue of $58.3M, representing 64% growth year-over-year. With the company's launch of a 34 milligram capsule of Nuplazid in Q3, Acadia CEO Steve Davis said: "We think with the new drug approved and as patients get more and more experience with a very favorable tolerability profile and the strong efficacy that we have that we'll be able to grow that market and physicians will likely begin treating earlier in the treatment paradigm." PRICE ACTION: Shares of Acadia are up approximately 5.8% to $20.89 in afternoon trading.

ACAD Acadia
$20.58

0.86 (4.36%)

11/07/18
HCWC
11/07/18
NO CHANGE
Target $60
HCWC
Buy
Acadia poised to outperform in 2019, says H.C. Wainwright
H.C. Wainwright analyst Andrew Fein expects to see Nuplazid regain momentum following Acadia Pharmaceuticals' Q3 results. As the overhang of the safety concerns around Nuplazid was cleared by the FDA's statement in September, the key commercial question is now whether the company will be able to regain the growth momentum through a number of promotional activities, Fein tells investors in a research note. He expects to see the "normalization of growth in the months ahead" and says Acadia is poised to outperform in 2019. Fein keeps a Buy rating on the shares with a $60 price target.
11/12/18
LEER
11/12/18
INITIATION
Target $21
LEER
Market Perform
Acadia initiated with a Market Perform at Leerink
Leerink Partners analyst Marc Goodman started Acadia Pharmaceuticals with a Market Perform rating and $21 price target.
11/13/18
LEER
11/13/18
INITIATION
Target $21
LEER
Market Perform
Acadia initiated with a Market Perform at Leerink
Leerink analyst Marc Goodman started Acadia with a Market Perform and $21 price target as he initiates Neuroscience space with a Positive View. The analyst believes the Neuroscience sector is experiencing a "renaissance" as multiple new agents and mechanisms are coming up the pipeline across major therapeutic areas, the number of clinical studies is growing nicely, and the FDA is friendly to innovation in this space, companies are getting smarter about speed-to-market strategies and selecting niche sub-populations to focus on for initial product approvals, payer pushback on usage is much lower than in other categories, and physicians are enthusiastic about new agents. Regarding Acadia, Goodman believes Nuplazid will rebound following the negative publicity regarding its safety profile based on his proprietary MEDACorp physician survey work, but consensus now assumes a rebound.
12/10/18
ADAM
12/10/18
INITIATION
Target $23
ADAM
Hold
Acadia initiated with a Hold at Canaccord
Canaccord analyst Sumant Kulkarni initiated Acadia Pharmaceuticals with a Hold rating and $23 price target. In a research note to investors, Kulkarni says that while he believes Acadia is a core holding for investors seeking exposure to central nervous system, or CNS, companies with commercial assets, he believes the risk/reward on the stock is balanced ahead of potential issuance of the company's initial 2019 outlook for Nuplazid in Parkinson's Disease psychosis, or PDP, and views his sales estimate for Nuplazid as "reasonable," though he admits he has low visibility heading into the event.

TODAY'S FREE FLY STORIES

AMZN

Amazon.com

$1,696.01

4.01 (0.24%)

07:14
01/22/19
01/22
07:14
01/22/19
07:14
Recommendations
Amazon.com analyst commentary  »

Amazon.com remains…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jan

  • 31

    Jan

  • 20

    Feb

  • 03

    Mar

CRSP

Crispr Therapeutics

$37.21

1.22 (3.39%)

07:14
01/22/19
01/22
07:14
01/22/19
07:14
Hot Stocks
Crispr Therapeutics signs collaboration agreement with ProBioGen »

Crispr Therapeutics and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

STZ

Constellation Brands

$164.13

3.78 (2.36%)

07:13
01/22/19
01/22
07:13
01/22/19
07:13
Initiation
Constellation Brands initiated  »

Constellation Brands…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Feb

HBM

Hudbay Minerals

$5.65

0.03 (0.53%)

07:12
01/22/19
01/22
07:12
01/22/19
07:12
Downgrade
Hudbay Minerals rating change  »

Hudbay Minerals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

CRSP

Crispr Therapeutics

$37.21

1.22 (3.39%)

07:12
01/22/19
01/22
07:12
01/22/19
07:12
Downgrade
Crispr Therapeutics rating change  »

Citi downgrades Crispr…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BTE

Baytex Energy

$1.92

-0.05 (-2.54%)

07:12
01/22/19
01/22
07:12
01/22/19
07:12
Downgrade
Baytex Energy rating change  »

Baytex Energy downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Feb

FB

Facebook

$150.01

1.77 (1.19%)

07:11
01/22/19
01/22
07:11
01/22/19
07:11
Periodicals
VC says Facebook the most 'vulnerable' big tech firm, CNBC reports »

Facebook is the most…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 24

    Jan

  • 30

    Jan

  • 25

    Feb

  • 03

    Mar

PEBO

Peoples Bancorp

$31.57

-0.11 (-0.35%)

07:11
01/22/19
01/22
07:11
01/22/19
07:11
Hot Stocks
Peoples Bancorp reports Q4 net interest margin 3.77% vs. 3.68% sequentially »

Compared to 3.63% for the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

AXGN

AxoGen

$16.00

0.64 (4.17%)

07:10
01/22/19
01/22
07:10
01/22/19
07:10
Hot Stocks
AxoGen appoints Eric Sandberg CCO »

AxoGen (AXGN) announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PEBO

Peoples Bancorp

$31.57

-0.11 (-0.35%)

07:10
01/22/19
01/22
07:10
01/22/19
07:10
Earnings
Peoples Bancorp reports Q4 EPS 71c, consensus 67c »

Earnings per diluted…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

CTSO

CytoSorbents

$7.66

0.04 (0.52%)

07:09
01/22/19
01/22
07:09
01/22/19
07:09
Hot Stocks
CytoSorbents expands partnership with Fresenius Medical Care to Korea and Mexico »

CytoSorbents announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WB

Weibo

$60.80

2.57 (4.41%)

07:09
01/22/19
01/22
07:09
01/22/19
07:09
Downgrade
Weibo rating change  »

Weibo downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DRNA

Dicerna

$10.76

-0.395 (-3.54%)

07:08
01/22/19
01/22
07:08
01/22/19
07:08
Upgrade
Dicerna rating change  »

Dicerna upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TRV

Travelers

$123.97

1.03 (0.84%)

07:07
01/22/19
01/22
07:07
01/22/19
07:07
Hot Stocks
Travelers reports Q4 return on equity 10.9% »

Reports Q4 core return on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

VYGR

Voyager Therapeutics

$8.27

-0.22 (-2.59%)

, RHHBY

Roche

$0.00

(0.00%)

07:07
01/22/19
01/22
07:07
01/22/19
07:07
Hot Stocks
Voyager Therapeutics names Robert Hesslein as general counsel »

Voyager Therapeutics…

VYGR

Voyager Therapeutics

$8.27

-0.22 (-2.59%)

RHHBY

Roche

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jan

  • 01

    Feb

  • 18

    Mar

CAPR

Capricor Therapeutics

$0.62

-0.007 (-1.11%)

07:07
01/22/19
01/22
07:07
01/22/19
07:07
Hot Stocks
Capricor Therapeutics announces outcome of FDA meeting for CAP-1002 »

Capricor Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AUPH

Aurinia Pharmaceuticals

$7.54

0.11 (1.48%)

07:07
01/22/19
01/22
07:07
01/22/19
07:07
Hot Stocks
Breaking Hot Stocks news story on Aurinia Pharmaceuticals »

Aurinia Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

REXR

Rexford Industrial

$32.00

0.225 (0.71%)

07:07
01/22/19
01/22
07:07
01/22/19
07:07
Hot Stocks
Rexford Industrial acquires two industrial properties for $27.6M »

Rexford Industrial Realty…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MDT

Medtronic

$87.31

-0.29 (-0.33%)

07:06
01/22/19
01/22
07:06
01/22/19
07:06
Hot Stocks
Medtronic announces new data shared on IN.PACT Admiral DCB »

Medtronic announced new…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jan

  • 18

    May

  • 28

    May

BG

Bunge

$52.95

0.745 (1.43%)

07:06
01/22/19
01/22
07:06
01/22/19
07:06
Hot Stocks
Bunge says Lupo, Bachrach, Boilini won't stand for re-election to board »

As part of Bunge's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AUPH

Aurinia Pharmaceuticals

$7.54

0.11 (1.48%)

07:05
01/22/19
01/22
07:05
01/22/19
07:05
Hot Stocks
Aurinia says VOS demonstrates statistically superior efficacy versus Restasis »

Aurinia Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

07:05
01/22/19
01/22
07:05
01/22/19
07:05
General news
Global stock markets under pressure after gloomy IMF report. »

Global stock markets…

BG

Bunge

$52.95

0.745 (1.43%)

07:04
01/22/19
01/22
07:04
01/22/19
07:04
Hot Stocks
Bunge sees FY18 total segment adjusted EBIT below previously disclosed range »

The company provided an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IPGP

IPG Photonics

$132.54

3.37 (2.61%)

07:04
01/22/19
01/22
07:04
01/22/19
07:04
Hot Stocks
IPG Photonics to acquire Padtec SND »

IPG Photonics announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CNC

Centene

$126.64

1.37 (1.09%)

07:04
01/22/19
01/22
07:04
01/22/19
07:04
Hot Stocks
Centene subsidiary selected by Arizona's Department of Corrections »

Centene announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Feb

  • 28

    May

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.